Otros idiomas Mirum Pharmaceuticals, Inc.

Acciones

MIRM

US6047491013

Tiempo real estimado Cboe BZX Otros sitios de cotización 16:53:12 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
25,22 ^USD	+0,60 %		+4,16 %	-13,84 %

17/04	MIRUM PHARMACEUTICALS, INC. : Stifel Nicolaus actualiza su recomendación a compra	ZM
02/04	Mirum Pharmaceuticals, Inc. recibe la recomendación positiva de reembolso para Livmarli (solución oral de maralixibat) por parte del Cadth de Canadá para pacientes con prurito colestásico en el síndrome de Alagille	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	11/04
Mirum Pharmaceuticals LIVMARLI Receives Positive Reimbursement Recommendation by Canada s CADTH for Patients with Cholestatic Pruritusin Alagille Syndrome	03/04
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome	02/04
LIVMARLI (solution orale de maralixibat) de Mirum Pharmaceuticals reçoit une recommandation de remboursement positive de l’ACMTS du Canada pour le traitement du prurit cholestatique chez les patients atteints du syndrome d’Alagille	02/04
Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome	02/04
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	14/03
Sector Update: Health Care	14/03
Mirum Pharmaceuticals Says FDA Approved Familial Intrahepatic Cholestasis Treatment	14/03
Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli	13/03
US FDA approves expanded use of Mirum's liver disease drug	13/03
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis	13/03
Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis	13/03
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	09/03
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences	05/03
Mirum Pharmaceuticals - Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI	01/03
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI	29/02
Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024	28/02
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q4 Revenue $69.6M, vs. Street Est of $67.9M	28/02
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update	28/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Mirum Pharmaceuticals, Inc.

Acciones

MIRM

US6047491013

Otros idiomas

Filtros